HonorStocks Biotech Gold Oil Mining China Asian MENU
Biotech Gold Oil Mining China Asian
Find Tomorrow's Winners Today

Stock technical analysis
Rating Flag Rating Flag Rating Flag Rating Flag Rating Flag
sell neutral buy
NovaBay Pharmaceuticals, Inc. (NBY)
1.08  -0.06  (-5.26%) 07-03 16:45
Open: 1.09 High: 1.11
Pre.close: 1.14 Low: 1.045
Volume: 2,542,746 Ave vol: 4,308,744
52w High: 1.85 52w Low: 0.24
MA(50): 0.937 MA(200): 0.755
EPS: -0.323 P/E Ratio: 0
Company profile
Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Website: http://www.novabay.com
Market Cap (M): 36
Shares Out (M): 33
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes non-antibiotic anti-infective products to address therapeutic needs of the anti-infective market in the United States and internationally. The company offers Avenova, a solution for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye, including the eyelid; CelleRx for the aesthetic dermatology market; and NeutroPhase for the wound care market. It also develops auriclosene, a synthetic molecule for use against bacteria, viruses, and fungi. The company has a collaboration and license agreement with Virbac to develop auriclosene for veterinary markets for companion animals. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.
Technical analysis
Overall: Underperform
MA: Bullish MACD: Bullish
KDJ: Bearish RSI: Bearish
Target 1: 1.55 Target 2: 1.81
Resist 1: 1.33 Resist 2: 1.55
Support 1: 1.01 Support 2: 0.81
Company key metrics
Revenue per Share: 0.3049
Net Income per Share: -0.4463
Cash per Share: 0.3205
Book Value per Share: 0.045
Price to Sales: 2.0005
Price to Book Value: 13.5673
Earnings Yield: -0.7316
Dividend Yield: 0
Debt to Equity: 10.5313
Debt to Assets: 0.9133
Financial analysis
Price to Book Value: Underperform
Return on Assets: Underperform
Return on Equity: Outperform
Discounted cash flow: Outperform
Price to Earnings: Underperform
Debt to Equity: Underperform
Stock Charts
Headline news
Thu, 25 Jun 2020
Riding the Trend or Protecting Profits: NovaBay Pharmaceuticals, Inc. (NBY) - The News Heater

Fri, 03 Jul 2020
A Little Luck Can Go a Long Way with NovaBay Pharmaceuticals Inc. (NBY) as it 5-day change was 1.89% - News Daemon

Tue, 30 Jun 2020
Growth Myths About NovaBay Pharmaceuticals, Inc. (NBY) You Probably Still Believe - The News Heater

Fri, 12 Jun 2020
Time to Pay a Little Attention to NovaBay Pharmaceuticals, Inc. (NBY) Again - The News Heater

Wed, 10 Jun 2020
Will NovaBay Pharmaceuticals, Inc. (NBY) Remain Competitive? - The News Heater

Thu, 11 Jun 2020
NovaBay Pharmaceuticals Inc. (NBY) average volume reaches $4.60M: Are the Stars Lining Up for Investors? - News Daemon

HonorStocks, Find Tomorrow's Winners Today

©HonorStocks.com | U.S. stock markets, stock quotes and stock analysis. Data and information is provided for informational purposes only, is not intended for trading purposes and is not investment advice. Neither HonorStocks.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Market data provided by: IEX and Financial Modeling Prep

Privacy Policy: Third parties, including Google, may be placing and reading cookies on your browsers, or other methods to collect information as a result of ad serving on this website. Google's use of advertising cookies enables it and its partners to serve ads to you based on your visit to this site and/or other sites on the Internet. You may opt out of personalized advertising by visiting Ads Settings. If you choose to use this website, you agree to the collection and use of information in relation to this policy. The information collected is used for providing and improving the ads Service. We will not use or share information with anyone, and we do not store any data from users.